Court opinion on Losec case a blow for originator firms
This article was originally published in Scrip
Executive Summary
In an opinion that will come as a disappointment to originator pharmaceutical companies, an advocate general of the Court of Justice of the EU has recommended that AstraZeneca's appeal against the fine imposed on it seven years ago for alleged abuse of a dominant position regarding its anti-ulcer medicine, Losec, should be dismissed.